• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向T细胞耗竭:非小细胞肺癌中的新兴策略

Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.

作者信息

Liu Xianqiang, Xi Xiaowei, Xu Shengshan, Chu Hongyu, Hu Penghui, Li Dong, Zhang Bin, Liu Hejie, Jiang Tianxiao, Lu Zhuming

机构信息

Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

Graduate School, Medical School of Chinese PLA, Beijing, China.

出版信息

Front Immunol. 2024 Dec 12;15:1507501. doi: 10.3389/fimmu.2024.1507501. eCollection 2024.

DOI:10.3389/fimmu.2024.1507501
PMID:39726592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11669709/
Abstract

Lung cancer continues to be a major contributor to cancer-related deaths globally. Recent advances in immunotherapy have introduced promising treatments targeting T cell functionality. Central to the efficacy of these therapies is the role of T cells, which are often rendered dysfunctional due to continuous antigenic stimulation in the tumor microenvironment-a condition referred to as T cell exhaustion. This review addresses the critical challenge of T cell exhaustion in non-small cell lung cancer (NSCLC), offering a detailed examination of its molecular underpinnings and the resultant therapeutic ineffectiveness. We synthesize current knowledge on the drivers of T cell exhaustion, evaluate emerging strategies for its reversal, and explore the potential impact of these insights for enhancing the clinical efficacy of immunotherapies. By consolidating reported clinical trials and preclinical studies, this article highlights innovative approaches to modulate immune responses and improve patient outcomes, thus providing a roadmap for future research and therapeutic development in lung cancer immunotherapy.

摘要

肺癌仍然是全球癌症相关死亡的主要原因。免疫疗法的最新进展带来了针对T细胞功能的有前景的治疗方法。这些疗法疗效的核心是T细胞的作用,由于肿瘤微环境中持续的抗原刺激,T细胞常常功能失调,这种情况被称为T细胞耗竭。本综述阐述了非小细胞肺癌(NSCLC)中T细胞耗竭这一关键挑战,详细探讨了其分子基础以及由此导致的治疗无效性。我们综合了关于T细胞耗竭驱动因素的现有知识,评估了逆转T细胞耗竭的新兴策略,并探讨了这些见解对提高免疫疗法临床疗效的潜在影响。通过整合已报道的临床试验和临床前研究,本文强调了调节免疫反应和改善患者预后的创新方法,从而为肺癌免疫疗法的未来研究和治疗发展提供了路线图。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d8c/11669709/48853b0aaa62/fimmu-15-1507501-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d8c/11669709/48853b0aaa62/fimmu-15-1507501-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d8c/11669709/48853b0aaa62/fimmu-15-1507501-g001.jpg

相似文献

1
Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer.靶向T细胞耗竭:非小细胞肺癌中的新兴策略
Front Immunol. 2024 Dec 12;15:1507501. doi: 10.3389/fimmu.2024.1507501. eCollection 2024.
2
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.非小细胞肺癌与肿瘤微环境:从靶向治疗迈向先进免疫治疗的进展
Front Immunol. 2025 Feb 10;16:1515748. doi: 10.3389/fimmu.2025.1515748. eCollection 2025.
3
High CD38 expression defines a mitochondrial function-adapted CD8 T cell subset with implications for lung cancer immunotherapy.高CD38表达定义了一种适应线粒体功能的CD8 T细胞亚群,对肺癌免疫治疗具有重要意义。
Cancer Immunol Immunother. 2025 Jan 3;74(2):49. doi: 10.1007/s00262-024-03881-5.
4
T cell exhaustion in human cancers.人类癌症中的 T 细胞耗竭。
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189162. doi: 10.1016/j.bbcan.2024.189162. Epub 2024 Jul 30.
5
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.T 淋巴细胞的独特耗竭特征塑造了肿瘤免疫微环境,这对非小细胞肺癌患者具有治疗意义。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-002780.
6
Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma.肿瘤微环境的细胞动力学驱动非小细胞肺癌的免疫治疗耐药性。
Cancer Lett. 2024 Nov 1;604:217272. doi: 10.1016/j.canlet.2024.217272. Epub 2024 Sep 24.
7
Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer.肿瘤浸润耗竭性T细胞分析凸显白细胞介素-6和程序性死亡受体1阻断作为非小细胞肺癌联合免疫治疗策略的作用。
Front Immunol. 2025 Feb 11;16:1486329. doi: 10.3389/fimmu.2025.1486329. eCollection 2025.
8
Reversal of T-cell exhaustion: Mechanisms and synergistic approaches.T 细胞耗竭的逆转:机制与协同策略。
Int Immunopharmacol. 2024 Sep 10;138:112571. doi: 10.1016/j.intimp.2024.112571. Epub 2024 Jun 27.
9
Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies.细胞可塑性与非小细胞肺癌:T细胞和NK细胞免疫逃逸及对免疫疗法耐药性获得的作用
Cancer Metastasis Rev. 2025 Jan 25;44(1):27. doi: 10.1007/s10555-025-10244-8.
10
CK2B Induces CD8 T-Cell Exhaustion through HDAC8-Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.CK2B通过HDAC8介导的表观遗传重编程诱导CD8 T细胞耗竭,以限制抗PD-1疗法在非小细胞肺癌中的疗效。
Adv Sci (Weinh). 2025 Apr;12(16):e2411053. doi: 10.1002/advs.202411053. Epub 2025 Feb 27.

引用本文的文献

1
Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.苯美司他巴特、安罗替尼与化疗用于广泛期小细胞肺癌患者的成本效益评估
Front Pharmacol. 2025 Aug 19;16:1524108. doi: 10.3389/fphar.2025.1524108. eCollection 2025.
2
A case report of thyroid myofibroblastic sarcoma.甲状腺肌成纤维细胞肉瘤病例报告
Medicine (Baltimore). 2025 Aug 29;104(35):e43992. doi: 10.1097/MD.0000000000043992.
3
Prognostic role and functional impact of cadherin genes in non-small cell lung cancer tumorigenesis: mechanistic insights from and analyses.

本文引用的文献

1
Molecular insight into T cell exhaustion in hepatocellular carcinoma.肝细胞癌中 T 细胞耗竭的分子机制研究。
Pharmacol Res. 2024 May;203:107161. doi: 10.1016/j.phrs.2024.107161. Epub 2024 Mar 29.
2
The complex role of IL-10 in malignant ascites: a review.IL-10 在恶性腹水的复杂作用:综述。
Cancer Immunol Immunother. 2024 Jan 27;73(2):32. doi: 10.1007/s00262-023-03616-y.
3
IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction.白细胞介素-10 通过诱导 PD-L1 抑制抗肿瘤免疫并促进肝转移。
钙黏蛋白基因在非小细胞肺癌肿瘤发生中的预后作用和功能影响:来自[具体研究]和[具体分析]的机制见解
PeerJ. 2025 Aug 19;13:e19785. doi: 10.7717/peerj.19785. eCollection 2025.
4
Global burden of nasopharyngeal carcinoma attributable to alcohol use: a 1990-2021 analysis with projections to 2040.饮酒所致鼻咽癌的全球负担:1990 - 2021年分析及至2040年的预测
Front Public Health. 2025 Aug 7;13:1623089. doi: 10.3389/fpubh.2025.1623089. eCollection 2025.
5
Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers.使用临床和血液生物标志物预测肺癌患者免疫治疗结果的列线图的开发与验证
BMC Cancer. 2025 Aug 22;25(1):1353. doi: 10.1186/s12885-025-14559-1.
6
Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer.评估新辅助免疫疗法联合化疗治疗Ⅲa期非小细胞肺癌的疗效。
Sci Rep. 2025 Jul 31;15(1):28003. doi: 10.1038/s41598-025-13917-0.
7
Resveratrol: A promising agent in targeting senescent cancer-associated fibroblasts to inhibit pancreatic cancer progression.白藜芦醇:一种靶向衰老的癌症相关成纤维细胞以抑制胰腺癌进展的有前景的药物。
World J Gastrointest Oncol. 2025 Jul 15;17(7):105034. doi: 10.4251/wjgo.v17.i7.105034.
8
Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report.多线免疫化疗和抗血管生成治疗后晚期肺大细胞神经内分泌癌的长期生存:一例报告
Front Immunol. 2025 Jun 30;16:1618672. doi: 10.3389/fimmu.2025.1618672. eCollection 2025.
9
Limited benefit of adjuvant chemotherapy for Asian patients with stage IB lung adenocarcinoma: implications for clinical practice.辅助化疗对亚洲IB期肺腺癌患者的获益有限:对临床实践的启示
World J Surg Oncol. 2025 Jul 7;23(1):267. doi: 10.1186/s12957-025-03907-x.
10
microRNA-196b-5p expression in cancer tissues is closely associated with clinical and pathological characteristics and prognosis of patients with non-small cell lung cancer.微小RNA-196b-5p在癌组织中的表达与非小细胞肺癌患者的临床病理特征及预后密切相关。
J Cardiothorac Surg. 2025 Jun 18;20(1):264. doi: 10.1186/s13019-025-03508-5.
J Hepatol. 2024 Apr;80(4):634-644. doi: 10.1016/j.jhep.2023.12.015. Epub 2023 Dec 30.
4
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors.组合阻断癌症免疫疗法:针对新兴免疫检查点受体。
Front Immunol. 2023 Oct 19;14:1264327. doi: 10.3389/fimmu.2023.1264327. eCollection 2023.
5
KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer.KLF12 转录调控非小细胞肺癌中 PD-L1 的表达。
Mol Oncol. 2023 Dec;17(12):2659-2674. doi: 10.1002/1878-0261.13512. Epub 2023 Sep 2.
6
Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy.肿瘤微环境中的非免疫细胞成分对肺癌免疫治疗的影响。
Biomed Pharmacother. 2023 Oct;166:115336. doi: 10.1016/j.biopha.2023.115336. Epub 2023 Aug 15.
7
Regulatory Mechanisms and Reversal of CD8T Cell Exhaustion: A Literature Review.CD8⁺T细胞耗竭的调控机制与逆转:文献综述
Biology (Basel). 2023 Apr 1;12(4):541. doi: 10.3390/biology12040541.
8
A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.一种新型浆细胞样树突状细胞疫苗联合抗 PD-1 治疗可扩增肺癌患者的肿瘤特异性 CD8+T 细胞。
Int J Mol Sci. 2023 Jan 18;24(3):1897. doi: 10.3390/ijms24031897.
9
PD-1 combination therapy with IL-2 modifies CD8 T cell exhaustion program.PD-1 联合 IL-2 治疗可改变 CD8 T 细胞衰竭程序。
Nature. 2022 Oct;610(7930):173-181. doi: 10.1038/s41586-022-05257-0. Epub 2022 Sep 28.
10
PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma.PVR/TIGIT和PD-L1/PD-1表达可预测肺鳞状细胞癌的生存率并为联合免疫治疗提供启示。
Transl Oncol. 2022 Oct;24:101501. doi: 10.1016/j.tranon.2022.101501. Epub 2022 Aug 1.